

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * <u>Alaska Permanent Fund Corp</u>  (Last) (First) (Middle) 801 WEST 10TH STREET SUITE 302  (Street) JUNEAU AK 99801  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/10/2019	3. Issuer Name and Ticker or Trading Symbol <u>Vir Biotechnology, Inc. [ VIR ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A-1 convertible preferred stock	(1)	(1)	Common Stock	10,000,000 <sup>(1)</sup>	(1)	I	By Yukon Investors, LLC
Series A-1 convertible preferred stock	(1)	(1)	Common Stock	3,000,000 <sup>(1)</sup>	(1)	I	By Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P
Series B convertible preferred stock	(1)	(1)	Common Stock	5,000,000 <sup>(1)</sup>	(1)	I	By Yukon Investors, LLC
Series B convertible preferred stock	(1)	(1)	Common Stock	250,000 <sup>(1)</sup>	(1)	I	By Altitude Life Science Ventures Fund II, L.P. and Altitude Life Science Ventures Side Fund II, L.P

**Explanation of Responses:**

1. All shares of Series A-1 convertible preferred stock, par value \$0.0001 per share and Series B convertible preferred stock, par value \$0.0001 per share, have no expiration date and will automatically convert into the Issuer's common stock on a 1-for-1 basis immediately prior to the closing of the Issuer's initial public offering.

**Remarks:**

The Reporting Person is the Alaska Permanent Fund Corporation, acting for and on behalf of the funds which the Alaska Permanent Fund Corporation is designated by Alaska Statutes 37.13 to manage and invest.

/s/ Angela Rodell 10/10/2019  
 \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.